Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Silo Pharma, Inc.
Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic
Today 14:30 EDT
From
Silo Pharma, Inc.
Via
GlobeNewswire
Tickers
SILO
Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide
August 07, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
Tickers
SILO
Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference
July 26, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
Tickers
SILO
Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
July 22, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
Tickers
SILO
Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
July 19, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
Tickers
SILO
Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15
July 18, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
Tickers
SILO
Silo Pharma Secures Exclusive Global License for Alzheimer's Therapeutic
July 16, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
Tickers
SILO
Silo Pharma Announces Exclusive, Global License for Lead Candidate SPC-15 Targeting PTSD and Stress-Induced Anxiety Disorders
July 08, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
Tickers
SILO
Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and Anxiety
June 26, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
Tickers
SILO
Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia
June 07, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
Tickers
SILO
Silo Pharma Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
June 06, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
Tickers
SILO
Silo Pharma Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
June 05, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
Tickers
SILO
Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety
June 04, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
Tickers
SILO
Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention
May 21, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
Tickers
SILO
Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine
May 14, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
Tickers
SILO
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
April 23, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
Tickers
SILO
Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic
April 10, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
Tickers
SILO
Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic
March 20, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
Tickers
SILO
Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain
March 18, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
Tickers
SILO
Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD
February 28, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
Tickers
SILO
Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery
February 14, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
Tickers
SILO
Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology
February 01, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
Tickers
SILO
Silo Pharma Announces Positive Results in Alzheimer’s Disease Study
January 24, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
Tickers
SILO
Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD
January 04, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
Tickers
SILO
Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia
December 28, 2023
From
Silo Pharma, Inc.
Via
GlobeNewswire
Tickers
SILO
Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD
November 21, 2023
From
Silo Pharma, Inc.
Via
GlobeNewswire
Tickers
SILO
Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD
November 08, 2023
From
Silo Pharma, Inc.
Via
GlobeNewswire
Tickers
SILO
Silo Pharma’s SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis
October 16, 2023
From
Silo Pharma, Inc.
Via
GlobeNewswire
Tickers
SILO
Silo Pharma Initiates Human Factor Study of SPC-15 for the Treatment of PTSD
October 11, 2023
From
Silo Pharma, Inc.
Via
GlobeNewswire
Tickers
SILO
Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA
September 20, 2023
From
Silo Pharma, Inc.
Via
GlobeNewswire
Tickers
SILO
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.